AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
AstraZeneca Stock and Partner Ionis Sink After Trial Failure. Alnylam Soars.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
AstraZeneca shares plunge as Wainua fails late-stage heart disease trial
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart condition, dealing a setback to one of its most closely watched pipeline assets. The stock fell about 9.5% in London trading, making it the biggest loser on the FTSE 100 index.
AstraZeneca's £19bn blow as Wainua heart drug fails key late-stage trial
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease. The drop propelled the stock to the top of the FTSE 100 losers' list.
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca stock dives 9% after heart drug trial misses target
AstraZeneca Says Wainua Trial Failed to Meet Primary Goal
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.
AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion
Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed to treat chronic respiratory diseases outside China for total payments of up to $1.9 billion.
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript
AstraZeneca PLC (AZN) Discusses Progress in Sustainability Strategy and the Role of AI in Healthcare Innovation Transcript
Citi keeps AstraZeneca on 'buy' ahead of second-quarter results
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has been kept on a 'buy' rating by Citi, which pointed to a run of late-stage drug trial results in the second half of the year as the key driver for the shares. The Wall Street bank was previewing second-quarter results from the Anglo-Swedish pharmaceuticals group, due on 27 July.
Here's Why Astrazeneca (AZN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Astrazeneca (AZN) Dipped More Than Broader Market Today
Astrazeneca (AZN) closed at $183.86 in the latest trading session, marking a -3.04% move from the prior day.
AZN vs. ILMN: Which Stock Should Value Investors Buy Now?
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Astrazeneca (AZN) and Illumina (ILMN). But which of these two stocks offers value investors a better bang for their buck right now?
